917827-92-0

Usage

Uses

Used in Pharmaceutical Industry:
cis-3-(Boc-aMinoMethyl)cyclobutanol is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its Boc-protected amino group allows for selective reactions and subsequent deprotection, enabling the creation of complex molecular structures with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, cis-3-(Boc-aMinoMethyl)cyclobutanol serves as a building block for the development of novel agrochemicals. Its unique structural features and reactivity contribute to the design of effective and targeted pest control agents, enhancing crop protection and yield.
Used in Fine Chemicals Industry:
cis-3-(Boc-aMinoMethyl)cyclobutanol is utilized as a versatile starting material in the synthesis of fine chemicals. Its Boc-protected amino group facilitates the formation of diverse chemical entities, which can be further modified to achieve specific properties and functions in various applications.
Used in Drug Discovery and Development:
Due to its versatile reactivity and structural features, cis-3-(Boc-aMinoMethyl)cyclobutanol plays a significant role in drug discovery and development. It can be employed in the design and synthesis of new drug candidates, potentially leading to the development of innovative treatments for various diseases and conditions.

InChI:InChI=1/C10H19NO3/c1-10(2,3)14-9(13)11-6-7-4-8(12)5-7/h7-8,12H,4-6H2,1-3H3,(H,11,13)/t7-,8+

Upstream product

• 167081-42-7 3-(aminomethyl)cyclobutanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 917827-89-5 N-benzyl-3-oxocyclobutanecarboxamide 

Relevant academic research and scientific papers

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS

The invention relates to compounds of the formula I, to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the formation or course of which protein kinases are involved.

HISTAMINE-3 RECEPTOR ANTAGONISTS

This invention is directed to a compound of the formula Ia or Ib. as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

Ornithine decarboxylase inhibiting cyclic aminooxy compounds

Compounds of formula (I): H2 N--(CH2)n --A--(CH2)m --O--NH2 and salts thereof are described in which the radical A is C3 -C6 cycloalkylene; n is 0 or 1 and, independen